Comparative Pharmacology
Head-to-head clinical analysis: NEXIUM versus YOSPRALA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEXIUM versus YOSPRALA.
NEXIUM vs YOSPRALA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme (proton pump) at the secretory surface of gastric parietal cells. It is the S-isomer of omeprazole and is a weak base that accumulates in the acidic environment of the parietal cell canaliculi, where it is converted to the active sulfenamide form that binds covalently to the proton pump, irreversibly inhibiting acid secretion.
Yosprala is a combination of aspirin (a nonsteroidal anti-inflammatory drug that inhibits cyclooxygenase-1 and cyclooxygenase-2, thereby reducing thromboxane A2 synthesis and platelet aggregation) and omeprazole (a proton pump inhibitor that inhibits gastric acid secretion by binding to the H+/K+ ATPase enzyme in gastric parietal cells).
20-40 mg orally once daily; IV: 20 mg once daily.
YOSPRALA (esomeprazole magnesium and naproxen) is available as delayed-release tablets containing 375 mg naproxen/20 mg esomeprazole or 500 mg naproxen/20 mg esomeprazole. The typical adult dose is one tablet twice daily, swallowed whole with liquid, at least 30 minutes before meals.
None Documented
None Documented
Approximately 1–1.5 hours in extensive CYP2C19 metabolizers; in poor metabolizers, half-life can be prolonged to 2–3 hours. Clinically, the plasma half-life does not directly correlate with the duration of acid suppression due to prolonged binding to the proton pump.
Naproxen: terminal elimination half-life is approximately 14 hours (range 12–17 hours), allowing twice-daily dosing. Esomeprazole: terminal half-life is approximately 1.2–1.5 hours after single dose, increasing to ~1.5–2.5 hours with repeated dosing due to saturation of CYP2C19. Clinical context: naproxen's half-life supports sustained analgesic/anti-inflammatory effect; esomeprazole's shorter half-life requires daily dosing for acid suppression.
Primarily hepatic metabolism via CYP2C19 and CYP3A4; approximately 80% of metabolites excreted in urine, and the remainder in feces via biliary elimination. Less than 1% of unchanged drug is excreted in urine.
YOSPRALA (esomeprazole and naproxen) is a fixed-dose combination. Naproxen is primarily excreted in urine as unchanged drug (approximately 60%) and as glucuronide conjugates (approximately 30%). Esomeprazole is extensively metabolized; less than 1% of the dose is excreted unchanged in urine. Biliary/fecal elimination accounts for the remainder via metabolites.
Category C
Category C
Proton Pump Inhibitor
Proton Pump Inhibitor